ES2572332T3 - 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides - Google Patents

2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides

Info

Publication number
ES2572332T3
ES2572332T3 ES08004779T ES08004779T ES2572332T3 ES 2572332 T3 ES2572332 T3 ES 2572332T3 ES 08004779 T ES08004779 T ES 08004779T ES 08004779 T ES08004779 T ES 08004779T ES 2572332 T3 ES2572332 T3 ES 2572332T3
Authority
ES
Spain
Prior art keywords
substituted
hydrogen
benzazocine
methane
opioid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES08004779T
Other languages
English (en)
Spanish (es)
Inventor
Mark P Wentland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rensselaer Polytechnic Institute
Original Assignee
Rensselaer Polytechnic Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytechnic Institute filed Critical Rensselaer Polytechnic Institute
Application granted granted Critical
Publication of ES2572332T3 publication Critical patent/ES2572332T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
ES08004779T 2000-10-31 2001-10-31 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides Expired - Lifetime ES2572332T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24443800P 2000-10-31 2000-10-31

Publications (1)

Publication Number Publication Date
ES2572332T3 true ES2572332T3 (es) 2016-05-31

Family

ID=22922766

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08004779T Expired - Lifetime ES2572332T3 (es) 2000-10-31 2001-10-31 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
ES03013544T Expired - Lifetime ES2304477T3 (es) 2000-10-31 2001-10-31 Procedimiento de preparacion de compuestos con afinidad a receptores opioides.
ES01992702T Expired - Lifetime ES2239170T3 (es) 2000-10-31 2001-10-31 2,6-metano-3-benzazocinas sustituidas en posicion 8 y morfinanos sustituidos en posicion 3 como agentes ligantes a receptores opioides.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES03013544T Expired - Lifetime ES2304477T3 (es) 2000-10-31 2001-10-31 Procedimiento de preparacion de compuestos con afinidad a receptores opioides.
ES01992702T Expired - Lifetime ES2239170T3 (es) 2000-10-31 2001-10-31 2,6-metano-3-benzazocinas sustituidas en posicion 8 y morfinanos sustituidos en posicion 3 como agentes ligantes a receptores opioides.

Country Status (9)

Country Link
US (9) US6784187B2 (cg-RX-API-DMAC7.html)
EP (3) EP1353909B1 (cg-RX-API-DMAC7.html)
JP (2) JP4340437B2 (cg-RX-API-DMAC7.html)
AT (2) ATE292625T1 (cg-RX-API-DMAC7.html)
AU (2) AU2713502A (cg-RX-API-DMAC7.html)
CA (1) CA2426942C (cg-RX-API-DMAC7.html)
DE (2) DE60133584T2 (cg-RX-API-DMAC7.html)
ES (3) ES2572332T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002036573A2 (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133584T2 (de) * 2000-10-31 2009-06-04 Rensselaer Polytechnic Institute 4-arylpiperidine als opioidrezeptorbindende agenzien
US6974824B2 (en) * 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
MXPA04011327A (es) * 2002-05-17 2005-08-15 Jenken Biosciences Inc Opioides y compuestos similares a opioides y usos de los mismos.
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
CA2518133A1 (en) * 2003-03-07 2004-09-16 Toray Industries Inc. Therapeutic agents for drug/substance dependence
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
NZ572901A (en) 2003-06-27 2010-06-25 Janssen Pharmaceutica Nv Tricyclic delta opioid modulators
EP1595541A1 (en) 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
KR101204751B1 (ko) * 2004-05-14 2012-11-27 얀센 파마슈티카 엔.브이. 카복사미도 아편유사약물 화합물
WO2007030089A1 (en) 2004-08-05 2007-03-15 Janssen Pharmaceutica N.V. Tricyclic delta- opioid modulators
TW200621785A (en) * 2004-11-04 2006-07-01 Toray Industries Analgesic
JP5198067B2 (ja) * 2004-11-05 2013-05-15 レンセラール ポリテクニック インスティチュート ４−ヒドロキシベンゾモルファン
BRPI0519201A2 (pt) 2004-12-22 2008-12-30 Janssen Pharmaceutica Nv moduladores de delta-opiàide tricÍclico
MX2007007626A (es) 2004-12-22 2008-01-28 Johnson & Johnson Moduladores delta-opioides triciclicos.
WO2006074388A2 (en) 2005-01-06 2006-07-13 Janssen Pharmaceutica N.V. TRICYCLIC δ-OPIOID MODULATORS
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
ATE490251T1 (de) 2005-06-16 2010-12-15 Janssen Pharmaceutica Nv Tricyclische opioidmodulatoren
JP5266051B2 (ja) 2005-07-21 2013-08-21 レンセラール ポリテクニック インスティチュート 大きい置換基を有する非フェノール性オピオイド
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
US8263807B2 (en) 2007-08-09 2012-09-11 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
JP5727374B2 (ja) * 2008-07-21 2015-06-03 レンセラール ポリテクニック インスティチュート 大型置換基を有する非フェノール性アミンオピオイド
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JP5798115B2 (ja) 2009-06-22 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 置換ヒドロキサム酸およびその使用
US10363251B2 (en) 2009-07-16 2019-07-30 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
HRP20191029T1 (hr) * 2009-12-04 2019-09-20 Alkermes Pharma Ireland Limited Derivati morfinana radi liječenja predoziranja lijekom
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011106627A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2550253B9 (en) 2010-03-22 2016-09-21 Rensselaer Polytechnic Institute Morphinane derivatives containing a carboxamide group as opioid receptor ligands
US8946223B2 (en) 2010-04-12 2015-02-03 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20120010412A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the Synthesis of Substituted Morphinans
JP5911484B2 (ja) 2010-07-16 2016-04-27 マリンクロッド エルエルシー トール様受容体９のアンタゴニストとしての（＋）−モルフィナンおよびその治療的使用
HUE065427T2 (hu) 2010-08-23 2024-05-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által indukált súlygyarapodás kezelésére
US8471026B2 (en) 2010-08-26 2013-06-25 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8778931B2 (en) 2010-12-22 2014-07-15 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US9029543B2 (en) 2011-04-05 2015-05-12 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
PL2725908T3 (pl) 2011-06-29 2017-10-31 Alkermes Inc Działające obwodowo związki opioidowe
MX375348B (es) 2011-12-15 2025-03-06 Alkermes Pharma Ireland Ltd Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
TW201431842A (zh) * 2012-11-09 2014-08-16 Purdue Pharma Lp 苯並嗎啡烷類似物及其應用
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
AU2014268361B2 (en) 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9688638B2 (en) 2013-11-27 2017-06-27 Nektar Therapeutics Opioid agonists and uses thereof
JP6386088B2 (ja) 2014-05-06 2018-09-05 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体及びその使用
SG10202100916PA (en) 2015-02-02 2021-02-25 Valo Early Discovery Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (cg-RX-API-DMAC7.html) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) * 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4374139A (en) * 1981-11-09 1983-02-15 Hoffmann-La Roche Inc. Levorotatory N-substituted acylmorphinans useful as analgesic agents
US4649200A (en) * 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) * 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) * 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) * 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0624095B2 (en) 1991-12-31 2005-07-20 Zymogenetics, Inc. Methods and compositions for reducing blood loss
EP0632041A1 (en) * 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
JP2000503019A (ja) * 1996-01-10 2000-03-14 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ 複素環縮合モルフィノイド誘導体（ｉｉ）
GB9709972D0 (en) * 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE60133584T2 (de) 2000-10-31 2009-06-04 Rensselaer Polytechnic Institute 4-arylpiperidine als opioidrezeptorbindende agenzien
US20050222204A1 (en) 2002-05-30 2005-10-06 Mitch Charles H Opioid receptor antagonists
JP5198067B2 (ja) * 2004-11-05 2013-05-15 レンセラール ポリテクニック インスティチュート ４−ヒドロキシベンゾモルファン
JP5266051B2 (ja) * 2005-07-21 2013-08-21 レンセラール ポリテクニック インスティチュート 大きい置換基を有する非フェノール性オピオイド

Also Published As

Publication number Publication date
US20040030138A1 (en) 2004-02-12
AU2002227135B2 (en) 2008-01-03
US8642615B2 (en) 2014-02-04
US20110207763A1 (en) 2011-08-25
EP1944292B1 (en) 2016-02-17
EP1359146A2 (en) 2003-11-05
US20090048447A1 (en) 2009-02-19
CA2426942C (en) 2014-06-03
EP1359146A3 (en) 2004-04-14
ES2239170T3 (es) 2005-09-16
ATE292625T1 (de) 2005-04-15
US8252929B2 (en) 2012-08-28
EP1944292B9 (en) 2016-07-06
AU2713502A (en) 2002-05-15
US7956187B2 (en) 2011-06-07
JP4340437B2 (ja) 2009-10-07
US6784187B2 (en) 2004-08-31
EP1359146B1 (en) 2008-04-09
US6887998B2 (en) 2005-05-03
US20050090519A1 (en) 2005-04-28
US20030187009A1 (en) 2003-10-02
EP1353909A2 (en) 2003-10-22
WO2002036573B1 (en) 2003-09-25
US20120302591A1 (en) 2012-11-29
DE60109960D1 (de) 2005-05-12
US9932349B2 (en) 2018-04-03
US20060030580A1 (en) 2006-02-09
DE60133584D1 (de) 2008-05-21
CA2426942A1 (en) 2002-05-10
US20140275545A1 (en) 2014-09-18
JP2004522706A (ja) 2004-07-29
ATE391712T1 (de) 2008-04-15
US20170217977A1 (en) 2017-08-03
EP1944292A1 (en) 2008-07-16
US7265226B2 (en) 2007-09-04
EP1353909B1 (en) 2005-04-06
ES2304477T3 (es) 2008-10-16
WO2002036573A3 (en) 2003-08-21
DE60109960T2 (de) 2006-02-16
JP2004137288A (ja) 2004-05-13
DE60133584T2 (de) 2009-06-04
WO2002036573A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
ES2572332T3 (es) 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
ATE413382T1 (de) Verbindungen, die als liganden des melanocortin- rezeptors fungieren
CO5200785A1 (es) Uso terapeutico de quinazolina
ATE314365T1 (de) Cyanopyrrole als progesteronrezeptoragonisten
AR028531A1 (es) Compuestos organicos
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
UY27597A1 (es) Inhibidores de acridona de la enzima impdh
HUP0000079A2 (hu) Indán- és dihidroindolszármazékok
TNSN07255A1 (en) Cyclohexylamides as dopamine d3, d2 and 5ht 1a antagonists
BG107120A (bg) Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства
ATE433962T1 (de) Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors
DE69815161D1 (de) Azindolethylaminderivate als Nikotin-acetylcholin-Rezeptor Bindung Verbindungen
PE20060562A1 (es) Derivados de amino-piperidina como agonistas de los receptores de melanocortina mc3 y/o mc4
DE69507293D1 (de) Benzamid-derivate als vasopressin-antagonisten
AP1816A (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
DE60027700D1 (de) Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
EA200400748A1 (ru) Агонисты рецепторов, активируемых пероксисомным пролифератором
TW200637559A (en) 3-propenylcefem derivative
AR033300A1 (es) Compuestos de cefem
HUP0001165A2 (hu) NK1 és NK2 antagonista hatású acil-amino-alkil-amid-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra
ES8702365A1 (es) Procedimiento para preparar nuevos derivados de benzazepina.
KR950702978A (ko) 아미드 유도체(Amide derivatives)
FI953784A0 (fi) 3'-atsiridinoantrasykliinijohdannaiset
IL179171A0 (en) Alkyl substituted indoloquinoxalines